NASDAQ:CNCE - Concert Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$14.84 -0.39 (-2.56 %)
(As of 10/19/2018 04:00 PM ET)
Previous Close$14.84
Today's Range$14.80 - $15.32
52-Week Range$12.33 - $30.71
Volume377,064 shs
Average Volume159,090 shs
Market Capitalization$356.61 million
P/E Ratio3.64
Dividend YieldN/A
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company. The company discovers and develops novel small molecule drugs for use in the treatment of various pulmonary diseases, including autoimmune and inflammatory diseases, and central nervous systems disorders. Its product candidates include AVP-786, a combination of deudextromethorphan and an ultra-low dose of quinidine, which is in Phase 3 clinical trials for the treatment of neurologic and psychiatric disorders, including agitation associated with Alzheimer's disease; CTP-730, a deuterated analog of apremilast that has completed the Phase 1 clinical trials for the treatment of inflammation or cancer; JZP-386, which has completed the Phase 1 clinical trials for the treatment of patients with narcolepsy; and CTP-543, which is in Phase 1 clinical trials for use in the treatment of alopecia areata. The company is also developing CTP-692, a selective deuterium-modified analog of the endogenous amino acid, D-serine, which is in preclinical studies for use in the treatment of patients with schizophrenia. It has strategic collaborations with Celgene Pharmaceuticals, Inc.; Celgene International Sarl; Celgene Corporation; Avanir Pharmaceuticals, Inc.; and Jazz Pharmaceuticals, Inc. The company was founded in 2006 and is headquartered in Lexington, Massachusetts.

Receive CNCE News and Ratings via Email

Sign-up to receive the latest news and ratings for CNCE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio33.93
Quick Ratio33.93


Trailing P/E Ratio3.64
Forward P/E Ratio-7.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$143.89 million
Price / Sales2.42
Cash Flow$4.1337 per share
Price / Cash3.59
Book Value$8.63 per share
Price / Book1.72


EPS (Most Recent Fiscal Year)$4.08
Net Income$95.63 million
Net Margins67.52%
Return on Equity-19.73%
Return on Assets-18.17%


Outstanding Shares23,420,000
Market Cap$356.61 million

Concert Pharmaceuticals (NASDAQ:CNCE) Frequently Asked Questions

What is Concert Pharmaceuticals' stock symbol?

Concert Pharmaceuticals trades on the NASDAQ under the ticker symbol "CNCE."

How were Concert Pharmaceuticals' earnings last quarter?

Concert Pharmaceuticals Inc (NASDAQ:CNCE) posted its quarterly earnings data on Thursday, August, 2nd. The biotechnology company reported ($0.57) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.05. Concert Pharmaceuticals had a negative return on equity of 19.73% and a net margin of 67.52%. View Concert Pharmaceuticals' Earnings History.

When is Concert Pharmaceuticals' next earnings date?

Concert Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, November 8th 2018. View Earnings Estimates for Concert Pharmaceuticals.

What price target have analysts set for CNCE?

5 brokerages have issued 12 month target prices for Concert Pharmaceuticals' stock. Their predictions range from $26.00 to $34.00. On average, they anticipate Concert Pharmaceuticals' share price to reach $28.50 in the next year. This suggests a possible upside of 92.0% from the stock's current price. View Analyst Price Targets for Concert Pharmaceuticals.

What is the consensus analysts' recommendation for Concert Pharmaceuticals?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Concert Pharmaceuticals in the last year. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Concert Pharmaceuticals.

What are Wall Street analysts saying about Concert Pharmaceuticals stock?

Here are some recent quotes from research analysts about Concert Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Concert Pharmaceuticals Inc. is a biopharmaceutical company. It is focused on applying its DCE Platform (R) to create novel small molecule drugs. The Company manufactures drugs in various therapeutic areas such as hot flashes, HIV, renal hepatic, neuropathic pain, MRSA infection, and schizophrenia, multiple tumors, and hyperparathyroidism. Concert Pharmaceuticals Inc. is based in United States. " (10/3/2018)
  • 2. Mizuho analysts commented, "We do not see earnings as the most meaningful indicator of value for a development-stage biotech. More importantly, Concert continues its steady progress on the clinical development front. A key catalyst is expected in 4Q18 with top-line readouts from the phase 2a trial of CTP-543 in alopecia areata at the 4 mg and 8 mg doses. A protocol amendment is also planned to evaluate the highest 12 mg dose. We anticipate data from the high-dose cohort will likely read out in 4Q19." (8/2/2018)

Who are some of Concert Pharmaceuticals' key competitors?

Who are Concert Pharmaceuticals' key executives?

Concert Pharmaceuticals' management team includes the folowing people:
  • Mr. Richard H. Aldrich, Co-Founder & Chairman (Age 64)
  • Dr. Roger D. Tung, Co-Founder, CEO, Pres & Director (Age 58)
  • Ms. Nancy Stuart, Chief Operating Officer (Age 60)
  • Dr. James V. Cassella, Chief Devel. Officer (Age 63)
  • Mr. Marc A. Becker, Chief Financial Officer (Age 46)

Who are Concert Pharmaceuticals' major shareholders?

Concert Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include First Manhattan Co. (2.41%) and MERIAN GLOBAL INVESTORS UK Ltd (0.11%). Company insiders that own Concert Pharmaceuticals stock include James V Cassella, Nancy Stuart, Richard Aldrich, Ronald W Barrett, Ryan Lynch and Value Fund L P Biotechnology. View Institutional Ownership Trends for Concert Pharmaceuticals.

Which institutional investors are buying Concert Pharmaceuticals stock?

CNCE stock was acquired by a variety of institutional investors in the last quarter, including First Manhattan Co. and MERIAN GLOBAL INVESTORS UK Ltd. View Insider Buying and Selling for Concert Pharmaceuticals.

How do I buy shares of Concert Pharmaceuticals?

Shares of CNCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Concert Pharmaceuticals' stock price today?

One share of CNCE stock can currently be purchased for approximately $14.84.

How big of a company is Concert Pharmaceuticals?

Concert Pharmaceuticals has a market capitalization of $356.61 million and generates $143.89 million in revenue each year. The biotechnology company earns $95.63 million in net income (profit) each year or $4.08 on an earnings per share basis. Concert Pharmaceuticals employs 64 workers across the globe.

What is Concert Pharmaceuticals' official website?

The official website for Concert Pharmaceuticals is

How can I contact Concert Pharmaceuticals?

Concert Pharmaceuticals' mailing address is 99 HAYDEN AVENUE SUITE 500, LEXINGTON MA, 02421. The biotechnology company can be reached via phone at 781-860-0045 or via email at [email protected]

MarketBeat Community Rating for Concert Pharmaceuticals (NASDAQ CNCE)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  258 (Vote Outperform)
Underperform Votes:  197 (Vote Underperform)
Total Votes:  455
MarketBeat's community ratings are surveys of what our community members think about Concert Pharmaceuticals and other stocks. Vote "Outperform" if you believe CNCE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CNCE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/20/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.

Yahoo Gemini Pixel